Vir Biotechnology is reducing its workforce by 25% to focus on its clinical-stage pipeline. The company will cut 140 jobs and incur $11-13 million in severance expenses.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Vir Biotechnology is reducing its workforce by 25% to focus on its clinical-stage pipeline. The company will cut 140 jobs and incur $11-13 million in severance expenses.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.